The 12 references in paper Ye. Ochakovskaya Yu., A. Kharkin V., G. Lobacheva V., N. Samsonova N., L. Klimovich G., L. Bockeria A., Е. Очаковская Ю., А. Харькин В., Г. Лобачева В., Н. Самсонова Н., Л. Климович Г., Л. Бокерия А. (2008) “Применение рекомбинантного активированного протеина С в терапии сепсиса у детей после кардиохирургических вмешательств // Use of Recombinant Activated Protein C in Therapy for Sepsis in Children after Cardiosurgical Interventions” / spz:neicon:reanimatology:791

1
Goldstein B., Simon N., Peters M. et al.Results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis. Pediatr. Crit. Care Med. 2006; 7 (3): 200.
(check this in PDF content)
2
Watson R. S., Carcillo J. A., LindeUZwirble et al.The epidemiology of severe sepsis in children in the United States. Amer. J. Respir. Crit. Care Med. 2003; 167: 695—701.
(check this in PDF content)
3
Graf J., Doig G. S., Cook D. J. et al.Randomizes, controlled clinical trials in sepsis: Has methodological quality improved over time? Crit. Care Med. 2002; 30 (2): 461—472.
(check this in PDF content)
4
Dellinger R. P., Carlet J. M., Masur H. et al.Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit. Care Med. 2004; 32: 858—873.
(check this in PDF content)
5
Bernard G. R., Vincent J. L., Laterre P. F. et al.Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 2001; 344: 699—709.
(check this in PDF content)
6
Riewald M., Petrovan R. J., Donner A. et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880—1882.
(check this in PDF content)
7
Joyce D. E., Gelbert L., Ciaccia A. et al.Gene expression profile of an tithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem. 2001; 276: 11199—11203.
(check this in PDF content)
8
Dhainaut J. F., Laterre P. F., Janes J. M. et al.Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multipleorgan dysfuntion: data from the PROWESS trial. Intens. Care Med. 2003; 29: 894—903.
(check this in PDF content)
9
Ely E. W., Laterre P. F., Angus D. C. et al. Drotrecogin alfa (activated) administration across clinical important subgroups of patients with severe sepsis. Crit. Care Med. 2003; 31: 1219.
(check this in PDF content)
10
Schein R. M. H., Kinasewitz G. T. Risk/benefit analysis for drotrecogin alfa (activated). Am. J. Surg. 2002; 184(suppl.): 25S—38S.
(check this in PDF content)
11
Bernard G., Macias W. L., Joyce D. E. et al.Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit. Care 2003; 7: 155—163.
(check this in PDF content)
12
US food and drug administration: Drotrecogin alfa (activated), Xigris, BLA #125029/0. FDA briefing information. US food and drug administration; 6 August 2001. [http://www.fda.gov/cber/label/droteli112101LB.pdf]. Поступила 15.08.07
(check this in PDF content)